Well, we have presented this year a poster here at ESMO about the molecular markers predictors of response for CIS patients, which is cohort 2 of the SunRISe-1 trial, treated with TAR-200 only and who harbored BCG and responsive CIS with or without papillary disease. It is true that it is not a very large cohort, it’s a small cohort, and we found that over 85% of the patients have some kind of genomic alteration, although we didn’t find any association of any of the alterations with the clinical outcomes...
Well, we have presented this year a poster here at ESMO about the molecular markers predictors of response for CIS patients, which is cohort 2 of the SunRISe-1 trial, treated with TAR-200 only and who harbored BCG and responsive CIS with or without papillary disease. It is true that it is not a very large cohort, it’s a small cohort, and we found that over 85% of the patients have some kind of genomic alteration, although we didn’t find any association of any of the alterations with the clinical outcomes. The most frequent alteration was 50% of the patients with TP53, but as I said, probably the small sample has not led us to find differences and predictors of response. Probably in the future, with the Sunrise 3 trial, which has over 600 patients treated with TAR-200, we might be able to find molecular predictors of response.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
